Flipping the switch from G1 to S phase with E3 ubiquitin ligases

Genes and Cancer

Volumn 3, Issue 11-12, 2012, Pages 634-648

  Rizzardi, Lindsay F ^a   Cook, Jeanette Gowen ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cdk; Cell cycle; Cyclin; DNA replication; E3 ubiquitin ligase; Origin licensing

Indexed keywords

APC PROTEIN; BORTEZOMIB; CELL CYCLE PROTEIN 6; CRL4 PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN E; CYCLINE; GEMININ; LIGASE; MELPHALAN; METHYLTRANSFERASE; PEVONEDISTAT; PR SET7 PROTEIN; PROTEASOME; PROTEIN C; PROTEIN P21; PROTEIN P27; REPLICATION LICENSING FACTOR CDT1; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR E2F; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UVOMORULIN;

CANCER THERAPY; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; COMPLEX FORMATION; DNA REPLICATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW;

EID: 84880482918     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912473307     Document Type: Review

References (232)

1. Olsen JV, Vermeulen M, Santamaria A, et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal. 2010;3(104):ra3
2. Wang Q, Moyret-Lalle C, Couzon F, et al. Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene. 2003;22(10):1486-1490
3. Yokoi S, Yasui K, Iizasa T, Takahashi T, Fujisawa T, Inazawa J. Down-regulation of SKP2 induces apoptosis in lung-cancer cells. Cancer Sci. 2003;94(4):344-349
4. Yokoi S, Yasui K, Mori M, Iizasa T, Fujisawa T, Inazawa J. Amplification and overexpression of SKP2 are associated with metastasis of nonsmall- cell lung cancers to lymph nodes. Am J Pathol. 2004;165(1):175-180
5. Dowen SE, Neutze DM, Pett MR, et al. Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes. Oncogene. 2003;22(16):2531-2540
6. DePamphilis ML. The "ORC cycle": a novel pathway for regulating eukaryotic DNA replication. Gene. 2003;310:1-15
7. Wei Z, Liu C, Wu X, et al. Characterization and structure determination of the Cdt1 binding domain of human minichromosome maintenance (Mcm) 6. J Biol Chem. 2010;285(17):12469-12473
8. Zhang J, Yu L, Wu X, et al. The interacting domains of hCdt1 and hMcm6 involved in the chromatin loading of the MCM complex in human cells. Cell Cycle. 2010;9(24):4848-4857
9. Cook J, Chasse D, Nevins J. The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells. J Biol Chem. 2004;279(10):9625-9633
10. Yanagi K-I, Mizuno T, You Z, Hanaoka F. Mouse geminin inhibits not only Cdt1-MCM6 interactions but also a novel intrinsic Cdt1 DNA binding activity. J Biol Chem. 2002;277(43):40871-40880
11. Chen S, de Vries MA, Bell SP. Orc6 is required for dynamic recruitment of Cdt1 during repeated Mcm2-7 loading. Genes Dev. 2007;21(22):2897-2890
12. Donovan S, Harwood J, Drury L, Diffley J. Cdc6p-dependent loading of Mcm proteins onto pre-replicative chromatin in budding yeast. Proc Natl Acad Sci U S A. 1997;94(11):5611-5616
13. Hua XH, Newport J. Identification of a preinitiation step in DNA replication that is independent of origin recognition complex and cdc6, but dependent on cdk2. J Cell Biol. 1998;140(2):271-281
14. Shen L, Nishioka T, Guo J, Chen C. Geminin functions downstream of p53 in K-ras-induced gene amplification of dihydrofolate reductase. Cancer Res. 2012;72:6153-6162
15. Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol. 2000;11(3):141-148
16. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503-533
17. Jackson S, Xiong Y. CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem Sci. 2009;34(11):562-570
18. Zimmerman ES, Schulman BA, Zheng N. Structural assembly of cullin-RING ubiquitin ligase complexes. Curr Opin Struct Biol. 2010;20(6):714-721
19. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6(5):369-381
20. Hayes MJ, Kimata Y, Wattam SL, et al. Early mitotic degradation of Nek2A depends on Cdc20-independent interaction with the APC/C. Nat Cell Biol. 2006;8(6):607-614
21. Buschhorn BA, Petzold G, Galova M, et al. Substrate binding on the APC/C occurs between the coactivator Cdh1 and the processivity factor Doc1. Nat Struct Mol Biol. 2011;18(1):6-13
22. da Fonseca PCA, Kong EH, Zhang Z, et al. Structures of APC/C(Cdh1) with substrates identify Cdh1 and Apc10 as the D-box co-receptor. Nature. 2011;470(7333):274-278
23. Yamano H, Gannon J, Mahbubani H, Hunt T. Cell cycle-regulated recognition of the destruction box of cyclin B by the APC/C in Xenopus egg extracts. Mol Cell. 2004;13(1):137-147
24. Burton JL, Solomon MJ. D box and KEN box motifs in budding yeast Hsl1p are required for APC-mediated degradation and direct binding to Cdc20p and Cdh1p. Genes Dev. 2001;15(18):2381-2395
25. Pfleger CM, Kirschner MW. The KEN box: an APC recognition signal distinct from the D box targeted by Cdh1. Genes Dev. 2000;14(6):655-665
26. Littlepage LE, Ruderman JV. Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev. 2002;16(17):2274-2285
27. Araki M, Yu H, Asano M. A novel motif governs APC-dependent degradation of Drosophila ORC1 in vivo. Genes Dev. 2005;19(20):2458-2465
28. McLean JR, Chaix D, Ohi MD, Gould KL. State of the APC/C: organization, function, and structure. Crit Rev Biochem Mol Biol. 2011;46(2):118-136
29. Song L, Rape M. Substrate-specific regulation of ubiquitination by the anaphase-promoting complex. Cell Cycle. 2011;10(1):52-5
30. Bar-On O, Shapira M, Skorecki K, Hershko A, Hershko DD. Regulation of APC/C (Cdh1) ubiquitin ligase in differentiation of human embryonic stem cells. Cell Cycle. 2010;9(10):1986-1989
31. Kramer ER, Scheuringer N, Podtelejnikov AV, Mann M, Peters JM. Mitotic regulation of the APC activator proteins CDC20 and CDH1. Mol Biol Cell. 2000;11(5):1555-1569
32. Zachariae W, Schwab M, Nasmyth K, Seufert W. Control of cyclin ubiquitination by CDK-regulated binding of Hct1 to the anaphase promoting complex. Science. 1998;282(5394):1721-1724
33. Jaspersen SL, Charles JF, Morgan DO. Inhibitory phosphorylation of the APC regulator Hct1 is controlled by the kinase Cdc28 and the phosphatase Cdc14. Curr Biol. 1999;9(5):227-236
34. Hsu JY, Reimann JDR, Sørensen CS, Lukas J, Jackson PK. E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). Nat Cell Biol. 2002;4(5):358-366
35. Di Fiore B, Pines J. Emi1 is needed to couple DNA replication with mitosis but does not regulate activation of the mitotic APC/C. J Cell Biol. 2007;177(3):425-447
36. Machida YJ, Dutta A. The APC/C inhibitor, Emi1, is essential for prevention of rereplication. Genes Dev. 2007;21(2):184-214
37. Williamson A, Wickliffe KE, Mellone BG, Song L, Karpen GH, Rape M. Identification of a physiological E2 module for the human anaphasepromoting complex. Proc Natl Acad Sci U S A. 2009;106(43):18213-18218
38. Rape M, Kirschner MW. Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature. 2004;432(7017):588-595
39. Peters J-M. The anaphase promoting complex/ cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol. 2006;7(9):644-656
40. Sigl R, Wandke C, Rauch V, Kirk J, Hunt T, Geley S. Loss of the mammalian APC/C activator FZR1 shortens G1 and lengthens S phase but has little effect on exit from mitosis. J Cell Sci. 2009;122(Pt 22):4208-4217
41. García-Higuera I, Manchado E, Dubus P, et al. Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nature. 2008;10(7):802-811
42. Engelbert D, Schnerch D, Baumgarten A, Wäsch R. The ubiquitin ligase APC(Cdh1) is required to maintain genome integrity in primary human cells. Oncogene. 2008;27(7):907-917
43. Rodier G, Coulombe P, Tanguay P-L, Boutonnet C, Meloche S. Phosphorylation of Skp2 regulated by CDK2 and Cdc14B protects it from degradation by APC(Cdh1) in G1 phase. EMBO J. 2008;27(4):679-691
44. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCF(Skp2- Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature. 2004;428(6979):190-193
45. Wei W, Ayad NG, Wan Y, Zhang G-J, Kirschner MW, Kaelin WG. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature. 2004;428(6979):194-198
46. Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, Harper JW. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 2004;18(21):2573-2580
47. Ungermannova D, Gao Y, Liu X. Ubiquitination of p27Kip1 requires physical interaction with cyclin E and probable phosphate recognition by SKP2. J Biol Chem. 2005;280(34):30301-30319
48. Orlicky S, Tang X, Willems A, Tyers M, Sicheri F. Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell. 2003;112(2):243-256
49. Hao B, Zheng N, Schulman BA, et al. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol Cell. 2005;20(1):9-19
50. Sitry D, Seeliger MA, Ko TK, et al. Three different binding sites of Cks1 are required for p27-ubiquitin ligation. J Biol Chem. 2002;277(44):42233-42240
51. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem. 2003;278(28):25752-25757
52. Frontini M, Kukalev A, Leo E, et al. The CDK subunit CKS2 counteracts CKS1 to control cyclin A/CDK2 activity in maintaining replicative fidelity and neurodevelopment. Dev Cell. 2012;23(2):356-370
53. Martinsson-Ahlzén H-S, Liberal V, Grünenfelder B, Chaves SR, Spruck CH, Reed SI. Cyclindependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells. Mol Cell Biol. 2008;28(18):5698-5709
54. Krishnan A, Nair SA, Pillai MR. Loss of cks1 homeostasis deregulates cell division cycle. J Cell Mol Med. 2010;14(1-2):154-164
55. Havens CG, Walter JC. Mechanism of CRL4(Cdt2), a PCNA-dependent E3 ubiquitin ligase. Genes Dev. 2011;25(15):1568-1582
56. Michishita M, Morimoto A, Ishii T, et al. Positively charged residues located downstream of PIP box, together with TD amino acids within PIP box, are important for CRL4(Cdt2) -mediated proteolysis. Genes Cells. 2011;16(1):12-22
57. Nakanishi M, Robetorye RS, Pereira-Smith OM, Smith JR. The C-terminal region of p21SDI1/ WAF1/CIP1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. J Biol Chem. 1995;270(29):17060-17063
58. Chuang L-C, Zhu X-N, Herrera CR, et al. The C-terminal domain of the Xenopus cyclin-dependent kinase inhibitor, p27Xic1, is both necessary and sufficient for phosphorylation-independent proteolysis. J Biol Chem. 2005;280(42):35290-35298
59. Havens CG, Walter JC. Docking of a specialized PIP Box onto chromatin-bound PCNA creates a degron for the ubiquitin ligase CRL4Cdt2. Mol Cell. 2009;35(1):93-104
60. Havens CG, Shobnam N, Guarino E, et al. Direct role for proliferating cell nuclear antigen in substrate recognition by the E3 ubiquitin ligase CRL4Cdt2. J Biol Chem. 2012;287(14): 11410-11421
61. Shiomi Y, Hayashi A, Ishii T, et al. Two different replication factor C proteins, Ctf18 and RFC1, separately control PCNA-CRL4Cdt2-mediated Cdt1 proteolysis during S phase and following UV irradiation. Mol Cell Biol. 2012;32(12):2279-2288
62. Wohlschlegel JA, Dwyer BT, Dhar SK, Cvetic C, Walter JC, Dutta A. Inhibition of eukaryotic DNA replication by geminin binding to Cdt1. Science. 2000;290(5500):2309-12
63. Tada S, Li A, Maiorano D, Mechali M, Blow JJ. Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin. Nat Cell Biol. 2001;3(2):107-113
64. Lee C, Hong B, Choi JM, et al. Structural basis for inhibition of the replication licensing factor Cdt1 by geminin. Nature. 2004;430(7002):913-917
65. De Marco V, Gillespie PJ, Li A, et al. Quaternary structure of the human Cdt1-Geminin complex regulates DNA replication licensing. Proc Natl Acad Sci U S A. 2009;106(47):19807-19812
66. Lutzmann M, Maiorano D, Méchali M. A Cdt1- geminin complex licenses chromatin for DNA replication and prevents rereplication during S phase in Xenopus. EMBO J. 2006;25(24): 5764-5774
67. Lutzmann M, Méchali M. MCM9 binds Cdt1 and is required for the assembly of prereplication complexes. Mol Cell. 2008;31(2):190-200
68. Caillat C, Perrakis A. Cdt1 and geminin in DNA replication initiation. Subcell Biochem. 2012;62:71-87
69. McGarry TJ, Kirschner MW. Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell. 1998;93(6):1043-1053
70. Shreeram S, Sparks A, Lane DP, Blow JJ. Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene. 2002;21(43):6624-6632
71. Sugimoto N, Kitabayashi I, Osano S, et al. Identification of novel human Cdt1-binding proteins by a proteomics approach: proteolytic regulation by APC/CCdh1. Mol Biol Cell. 2008;19(3): 1007-1021
72. Shen Z, Chakraborty A, Jain A, et al. Dynamic association of ORCA with prereplicative complex components regulates DNA replication initiation. Mol Cell Biol. 2012;32(15):3107-3120
73. Shen Z, Sathyan KM, Geng Y, et al. A WDrepeat protein stabilizes ORC binding to chromatin. Mol Cell. 2010;40(1):99-111
74. Petersen BO, Wagener C, Marinoni F. Cell cycleand cell growth-regulated proteolysis of mammalian CDC6 is dependent on APC-CDH1. Genes Dev. 2000;14:2330-2343
75. Mailand N, Diffley JFX. CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell. 2005;122(6):915-926
76. Gillespie PJ, Li A, Blow JJ. Reconstitution of licensed replication origins on Xenopus sperm nuclei using purified proteins. BMC Biochem. 2001;2:15
77. Houston SI, McManus KJ, Adams MM, et al. Catalytic function of the PR-Set7 histone H4 lysine 20 monomethyltransferase is essential for mitotic entry and genomic stability. J Biol Chem. 2008;283(28):19478-19488
78. Oda H, Okamoto I, Murphy N, et al. Monomethylation of histone H4-lysine 20 is involved in chromosome structure and stability and is essential for mouse development. Mol Cell Biol. 2009;29(8):2278-2295
79. Tardat M, Brustel J, Kirsh O, et al. The histone H4 Lys 20 methyltransferase PR-Set7 regulates replication origins in mammalian cells. Nat Cell Biol. 2010;12(11):1086-1093
80. Kalakonda N, Fischle W, Boccuni P, et al. Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1. Oncogene. 2008;27(31):4293-4304
81. Gurvich N, Perna F, Farina A, et al. L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc Natl Acad Sci U S A. 2010;107(52):22552-22527
82. Oda H, Hübner MR, Beck DB, et al. Regulation of the histone H4 monomethylase PR-Set7 by CRL4(Cdt2)-mediated PCNA-dependent degradation during DNA damage. Mol Cell. 2010;40(3):364-376
83. Rice JC, Nishioka K, Sarma K, Steward R, Reinberg D, Allis CD. Mitotic-specific methylation of histone H4 Lys 20 follows increased PR-Set7 expression and its localization to mitotic chromosomes. Genes Dev. 2002;16(17):2225-2230
84. Wu S, Wang W, Kong X, et al. Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression. Genes Dev. 2010;24(22):2531-42
85. Pesavento JJ, Yang H, Kelleher NL, Mizzen CA. Certain and progressive methylation of histone H4 at lysine 20 during the cell cycle. Mol Cell Biol. 2008;28(1):468-486
86. Schotta G, Sengupta R, Kubicek S, et al. A chromatin- wide transition to H4K20 monomethylation impairs genome integrity and programmed DNA rearrangements in the mouse. Genes Dev. 2008;22(15):2048-2061
87. Yang H, Pesavento JJ, Starnes TW, et al. Preferential dimethylation of histone H4 lysine 20 by Suv4-20. J Biol Chem. 2008;283(18):12085-12092
88. Vermeulen M, Eberl HC, Matarese F, et al. Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Cell. 2010;142(6):967-980
89. Shi X, Kachirskaia I, Yamaguchi H, et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell. 2007;27(4):636-46
90. Tardat M, Murr R, Herceg Z, Sardet C, Julien E. PR-Set7-dependent lysine methylation ensures genome replication and stability through S phase. J Cell Biol. 2007;179(7):1413-1426
91. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215-221
92. Wong JV, Dong P, Nevins JR, Mathey-Prevot B, You L. Network calisthenics: control of E2F dynamics in cell cycle entry. Cell Cycle. 2011;10(18):3086-94
93. Tsai S-Y, Opavsky R, Sharma N, et al. Mouse development with a single E2F activator. Nature. 2008;454(7208):1137-1141
94. Wells J, Boyd KE, Fry CJ, Bartley SM, Farnham PJ. Target gene specificity of E2F and pocket protein family members in living cells. Mol Cell Biol. 2000;20(16):5797-5807
95. Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev. 2000;14(7):804-816
96. Henley SA, Dick FA. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div. 2012;7(1):10
97. Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ. 1998;9(8):585-593
98. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18(2):753-761
99. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998;12(15):2245-2262
100. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet. 2001;10(7):699-703
101. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002;3(1):11-20
102. Bartkova J, Hořejší Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434(7035):864-870
103. Pickering MT, Kowalik TF. Rb inactivation leads to E2F1-mediated DNA doublestrand break accumulation. Oncogene. 2006;25(5):746-755
104. Budhavarapu VN, White ED, Mahanic CS. Regulation of E2F1 by APC/CCdh1 via K11 linkage-specific ubiquitin chain formation. Cell cycle (Georgetown, Tex). 2012;11:2030-2038
105. Ping Z, Lim R, Bashir T, Pagano M, Guardavaccaro D. APC/CCdh1 controls the proteasomemediated degradation of E2F3 during cell cycle exit. Landes Bioscience. 2012;11(10):1999-2005
106. Peart MJ, Poyurovsky MV, Kass EM, et al. APC/C(Cdc20) targets E2F1 for degradation in prometaphase. Cell Cycle. 2010;9(19):3956-3964
107. Takeda S, Chen DY, Westergard TD, et al. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev. 2006;20(17):2397-2409
108. Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002;10(5): 1107-1117
109. Wang P, Lin C, Smith ER, et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1- mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol Cell Biol. 2009;29(22):6074-6085
110. Tyagi S, Chabes AL, Wysocka J, Herr W. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol Cell. 2007;27(1):107-119
111. Liu H, Cheng EH-Y, Hsieh JJ-D. Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev. 2007;21(19):2385-2398
112. Wong PG, Glozak MA, Cao TV, Vaziri C, Seto E, Alexandrow MG. Chromatin unfolding by Cdt1 regulates MCM loading via opposing functions of HBO1 and HDAC11-geminin. Cell Cycle. 2010;9(21)
113. Miotto B, Struhl K. HBO1 histone acetylase is a coactivator of the replication licensing factor Cdt1. Genes Dev. 2008;22(19):2633-2638
114. Miotto B, Struhl K. HBO1 histone acetylase activity is essential for DNA replication licensing and inhibited by Geminin. Mol Cell. 2010;37(1):57-66
115. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501-1512
116. Johnson DG, Schneider-Broussard R. Role of E2F in cell cycle control and cancer. Front Biosci. 1998;3:d447-d448
117. Suzuki T, K-Tsuzuku J, Ajima R, Nakamura T, Yoshida Y, Yamamoto T. Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. Genes Dev. 2002;16(11):1356-1370
118. Hiramatsu Y, Kitagawa K, Suzuki T, et al. Degradation of Tob1 mediated by SCFSkp2- dependent ubiquitination. Cancer Res. 2006;66(17):8477-8483
119. Yoshida Y, Nakamura T, Komoda M, et al. Mice lacking a transcriptional corepressor Tob are predisposed to cancer. Genes Dev. 2003;17(10):1201-1206
120. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7(10):750-762
121. Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer. 2001;34(2):207-218
122. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat. 1998;52(1- 3):1-15
123. Bartkova J, Lukas J, Müller H, Strauss M, Gusterson B, Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res. 1995;55(4):949-956
124. Shamma A, Doki Y, Shiozaki H, et al. Cyclin D1 overexpression in esophageal dysplasia: a possible biomarker for carcinogenesis of esophageal squamous cell carcinoma. Int J Oncol. 2000;16(2):261-266
125. Vlach J, Hennecke S, Amati B. Phosphorylation- dependent degradation of the cyclindependent kinase inhibitor p27. EMBO J. 1997;16(17):5334-5344
126. Montagnoli A, Fiore F, Eytan E, et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 1999;13(9):1181-1189
127. Grimmler M, Wang Y, Mund T, et al. Cdkinhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell. 2007;128(2):269-280
128. Chu I, Sun J, Arnaout A, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell. 2007;128(2):281-294
129. Zhu H, Nie L, Maki CG. Cdk2-dependent inhibition of p21 stability via a C-terminal cyclin-binding motif. J Biol Chem. 2005;280(32):29282-29288
130. Kim G-Y, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem. 2002;277(33):29792-802
131. Yao Z-P, Zhou M, Kelly SE, Seeliger MA, Robinson CV, Itzhaki LS. Activation of ubiquitin ligase SCF(Skp2) by Cks1: insights from hydrogen exchange mass spectrometry. J Mol Biol. 2006;363(3):673-686
132. Spruck C, Strohmaier H, Watson M, et al. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol Cell. 2001;7(3):639-650
133. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002;8(10):1153-1160
134. Kfir S, Ehrlich M, Goldshmid A, Liu X, Kloog Y, Henis YI. Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling. Mol Cell Biol. 2005;25(18):8239-8250
135. Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev. 2006;20(1):47-64
136. Kamura T, Hara T, Matsumoto M, et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol. 2004;6(12):1229-1235
137. Kotoshiba S, Kamura T, Hara T, Ishida N, Nakayama KI. Molecular dissection of the interaction between p27 and Kip1 ubiquitylation- promoting complex, the ubiquitin ligase that regulates proteolysis of p27 in G1 phase. J Biol Chem. 2005;280(18):17694-700
138. Hara T, Kamura T, Kotoshiba S, et al. Role of the UBL-UBA protein KPC2 in degradation of p27 at G1 phase of the cell cycle. Mol Cell Biol. 2005;25(21):9292-9303
139. Sclafani R, Holzen T. Cell cycle regulation of DNA replication. Annu Rev Genet. 2007;41:237-280
140. Lin JJ, Dutta A. ATR pathway is the primary pathway for activating G2/M checkpoint induction after re-replication. J Biol Chem. 2007;282(42): 30357-30362
141. Liu E, Lee A, Chiba T, Olson E, Sun P, Wu X. The ATR-mediated S phase checkpoint prevents rereplication in mammalian cells when licensing control is disrupted. J Cell Biol. 2007;179(4):643-657
142. Green BM, Finn KJ, Li JJ. Loss of DNA replication control is a potent inducer of gene amplification. Science. 2010;329(5994):943-946
143. Nishitani H, Sugimoto N, Roukos V, et al. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1- Cul4, target human Cdt1 for proteolysis. EMBO J. 2006;25(5):1126-1136
144. Arias EE, Walter JC. Strength in numbers: preventing rereplication via multiple mechanisms in eukaryotic cells. Genes Dev. 2007;21(5):497-518
145. Higa LAA, Mihaylov IS, Banks DP, Zheng J, Zhang H. Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol. 2003; 5(11):1008-1015
146. Machida Y, Hamlin J, Dutta A. Right place, right time, and only once: replication initiation in metazoans. Cell. 2005;123(1):13-24
147. Teer JK, Machida YJ, Labit H, et al. Proliferating human cells hypomorphic for origin recognition complex 2 and pre-replicative complex formation have a defect in p53 activation and Cdk2 kinase activation. J Biol Chem. 2006;281(10):6253-6260
148. Arias EE, Walter JC. Replication-dependent destruction of Cdt1 limits DNA replication to a single round per cell cycle in Xenopus egg extracts. Genes Dev. 2005;19(1):114-126
149. Arias EE, Walter JC. PCNA functions as a molecular platform to trigger Cdt1 destruction and prevent re-replication. Nat Cell Biol. 2006;8(1):84-90
150. Guarino E, Shepherd MEA, Salguero I, Hua H, Deegan RS, Kearsey SE. Cdt1 proteolysis is promoted by dual PIP degrons and is modulated by PCNA ubiquitylation. Nucleic Acids Res. 2011;39(14):5978-5990
151. Vaziri C, Saxena S, Jeon Y, et al. A p53-dependent checkpoint pathway prevents rereplication. Mol Cell. 2003;11(4):997-1008
152. Li A, Blow JJ. Cdt1 downregulation by proteolysis and geminin inhibition prevents DNA re-replication in Xenopus. EMBO J. 2005;24(2):395-404
153. Takeda DY, Parvin JD, Dutta A. Degradation of Cdt1 during S phase is Skp2-independent and is required for efficient progression of mammalian cells through S phase. J Biol Chem. 2005;280(24):23416-23423
154. Yoshida K, Takisawa H, Kubota Y. Intrinsic nuclear import activity of geminin is essential to prevent re-initiation of DNA replication in Xenopus eggs. Genes Cells. 2005;10(1): 63-73
155. Kerns SL, Torke SJ, Benjamin JM, McGarry TJ. Geminin prevents rereplication during xenopus development. J Biol Chem. 2007;282(8): 5514-5521
156. Raman M, Havens CG, Walter JC, Harper JW. A genome-wide screen identifies p97 as an essential regulator of DNA damage-dependent CDT1 destruction. Mol Cell. 2011;44(1):72-84
157. Miotto B, Struhl K. JNK1 phosphorylation of Cdt1 inhibits recruitment of HBO1 histone acetylase and blocks replication licensing in response to stress. Mol Cell. 2011;44(1):62-71
158. Chandrasekaran S, Tan TX, Hall JR, Cook JG. Stress-stimulated mitogen-activated protein kinases control the stability and activity of the Cdt1 DNA replication licensing factor. Mol Cell Biol. 2011;31(22):4405-4416
159. Varma D, Chandrasekaran S, Sundin LJR, et al. Recruitment of the human Cdt1 replication licensing protein by the loop domain of Hec1 is required for stable kinetochore-microtubule attachment. Nature. 2012;14(6):593-603
160. Glozak MA, Seto E. Acetylation/deacetylation modulates the stability of DNA replication licensing factor Cdt1. J Biol Chem. 2009;284(17):11446-11453
161. Shen Z, Prasanth SG. Orc2 protects ORCA from ubiquitin-mediated degradation. Cell Cycle. 2012;11(19):3578-3589
162. Paolinelli R, Mendoza-Maldonado R, Cereseto A, Giacca M. Acetylation by GCN5 regulates CDC6 phosphorylation in the S phase of the cell cycle. Nat Struct Mol Biol. 2009;16(4):412-420
163. Jiang W, Wells NJ, Hunter T. Multistep regulation of DNA replication by Cdk phosphorylation of HsCdc6. Proc Natl Acad Sci U S A. 1999;96(11):6193-6198
164. Petersen BO, Lukas J, Sørensen CS, Bartek J, Helin K. Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization. EMBO J. 1999;18(2):396-410
165. Abbas T, Shibata E, Park J, Jha S, Karnani N, Dutta A. CRL4(Cdt2) regulates cell proliferation and histone gene expression by targeting PR-Set7/Set8 for degradation. Mol Cell. 2010;40(1):9-21
166. Centore RC, Havens CG, Manning AL, et al. CRL4Cdt2-mediated destruction of the histone methyltransferase Set8 prevents premature chromatin compaction in S phase. Mol Cell. 2010;40(1):22-33
167. Marti A, Wirbelauer C, Scheffner M, Krek W. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol. 1999;1(1):14-19
168. Shan B, Lee WH. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol. 1994;14(12):8166-8173
169. Kowalik TF, DeGregori J, Schwarz JK, Nevins JR. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol. 1995;69(4):2491-2500
170. Sun B, Wingate H, Swisher SG, Keyomarsi K, Hunt KK. Absence of pRb facilitates E2F1- induced apoptosis in breast cancer cells. Cell Cycle. 2010;9(6):1122-1130
171. Liu H, Takeda S, Kumar R, et al. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature. 2010;467(7313):343-346
172. Pagano M, Theodoras AM, Tam SW, Draetta GF. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev. 1994;8(14):1627-39
173. Guo Y, Harwalkar J, Stacey DW, Hitomi M. Destabilization of cyclin D1 message plays a critical role in cell cycle exit upon mitogen withdrawal. Oncogene. 2005;24(6):1032-1042
174. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12(22):3499-3511
175. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997;11(8):957-972
176. Hitomi M, Yang K, Stacey AW, Stacey DW. Phosphorylation of cyclin D1 regulated by ATM or ATR controls cell cycle progression. Mol Cell Biol. 2008;28(17):5478-9543
177. Aggarwal P, Lessie MD, Lin DI, et al. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev. 2007;21(22):2908-2922
178. Barbash O, Zamfirova P, Lin DI, et al. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell. 2008;14(1):68-78
179. Lin DI, Barbash O, Kumar KGS, et al. Phosphorylation- dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell. 2006;24(3):355-366
180. Okabe H, Lee S-H, Phuchareon J, Albertson DG, McCormick F, Tetsu O. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One. 2006;1:e128
181. Santra MK, Wajapeyee N, Green MR. F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature. 2009;459(7247):722-725
182. Vaites LP, Lee EK, Lian Z, et al. The Fbx4 tumor suppressor regulates cyclin D1 accumulation and prevents neoplastic transformation. Mol Cell Biol. 2011;31(22):4513-4523
183. Kanie T, Onoyama I, Matsumoto A, et al. Genetic reevaluation of the role of F-box proteins in cyclin D1 degradation. Mol Cell Biol. 2012;32(3):590-605
184. Mori T, Ikeda DD, Fukushima T, Takenoshita S, Kochi H. NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor. Cell Cycle. 2011;10(19):3284-3299
185. Li Y, Mori T, Hata H, Homma Y, Kochi H. NIRF induces G1 arrest and associates with Cdk2. Biochem Biophys Res Commun. 2004;319(2):464-468
186. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin- proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 1996;10(16):1979-1990
187. Koepp DM, Schaefer LK, Ye X, et al. Phosphorylation- dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 2001;294(5540):173-177
188. Welcker M, Singer J, Loeb KR, et al. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell. 2003;12(2): 381-392
189. Grim JE, Gustafson MP, Hirata RK, et al. Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase. J Cell Biol. 2008;181(6):913-920
190. Minella AC, Loeb KR, Knecht A, et al. Cyclin E phosphorylation regulates cell proliferation in hematopoietic and epithelial lineages in vivo. Genes Dev. 2008;22(12):1677-1689
191. Zou Y, Mi J, Cui J, et al. Characterization of nuclear localization signal in the N terminus of CUL4B and its essential role in cyclin E degradation and cell cycle progression. J Biol Chem. 2009;284(48):33320-33332
192. Abbas T, Sivaprasad U, Terai K, Amador V, Pagano M, Dutta A. PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex. Genes Dev. 2008;22(18):2496-2506
193. Kim Y, Starostina NG, Kipreos ET. The CRL4Cdt2 ubiquitin ligase targets the degradation of p21Cip1 to control replication licensing. Genes Dev. 2008;22:2507-2519
194. Nishitani H, Shiomi Y, Iida H, Michishita M, Takami T, Tsurimoto T. CDK inhibitor p21 is degraded by a proliferating cell nuclear antigencoupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J Biol Chem. 2008;283(43):29045-29052
195. Stuart SA, Wang JYJ. Ionizing radiation induces ATM-independent degradation of p21Cip1 in transformed cells. J Biol Chem. 2009;284(22):15061-15070
196. Li B, Jia N, Kapur R, Chun KT. Cul4A targets p27 for degradation and regulates proliferation, cell cycle exit, and differentiation during erythropoiesis. Blood. 2006;107(11):4291-4299
197. Miranda-Carboni GA, Krum SA, Yee K, et al. A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors. Genes Dev. 2008;22(22):3121-3134
198. Abbas T, Dutta A. CRL4Cdt2: master coordinator of cell cycle progression and genome stability. Cell Cycle. 2011;10(2):241-249
199. Bondar T, Kalinina A, Khair L, et al. Cul4A and DDB1 associate with Skp2 to target p27Kip1 for proteolysis involving the COP9 signalosome. Mol Cell Biol. 2006;26(7):2531-2539
200. Higa LA, Wu M, Ye T, Kobayashi R, Sun H, Zhang H. CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat Cell Biol. 2006;8(11):1277-1283
201. Cang Y, Zhang J, Nicholas SA, et al. Deletion of DDB1 in mouse brain and lens leads to p53-dependent elimination of proliferating cells. Cell. 2006;127(5):929-940
202. Yan Y, Zhang X, Legerski RJ. Artemis interacts with the Cul4A-DDB1DDB2 ubiquitin E3 ligase and regulates degradation of the CDK inhibitor p27. Cell Cycle. 2011;10(23):4098-4109
203. Dorn E, Chastain P, Hall J, Cook J. Analysis of re-replication from deregulated origin licensing by DNA fiber spreading. Nucleic Acids Res. 2009;37(1):60-69
204. Hall J, Lee H, Bunker B, et al. Cdt1 and Cdc6 are destabilized by rereplication-induced DNA damage. J Biol Chem. 2008;283(37):25356-25363
205. Zhu W, DePamphilis ML. Selective killing of cancer cells by suppression of geminin activity. Cancer Res. 2009;69(11):4870-4877
206. Xouri G, Lygerou Z, Nishitani H, Pachnis V, Nurse P, Taraviras S. Cdt1 and geminin are down-regulated upon cell cycle exit and are over-expressed in cancer-derived cell lines. Eur J Biochem. 2004;271(16):3368-3378
207. Blow JJ, Gillespie PJ. Replication licensing and cancer-a fatal entanglement? Nat Rev Cancer. 2008;8(10):799-806
208. Gonzalez MA, Tachibana K-EK, Laskey RA, Coleman N. Control of DNA replication and its potential clinical exploitation. Nat Rev Cancer. 2005;5(2):135-141
209. Arentson E, Faloon P, Seo J, et al. Oncogenic potential of the DNA replication licensing protein CDT1. Oncogene. 2002;21(8):1150-1158
210. Liontos M, Koutsami M, Sideridou M, et al. Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res. 2007;67(22):10899-10909
211. Karakaidos P, Taraviras S, Vassiliou LV, et al. Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect with mutant p53 on tumor growth and chromosomal instability-evidence of E2F-1 transcriptional control over hCdt1. Am J Pathol. 2004;165(4):1351-1365
212. Seo J, Chung YS, Sharma GG, et al. Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53. Oncogene. 2005;24(55):8176-8186
213. Melixetian M, Ballabeni A, Masiero L, et al. Loss of geminin induces rereplication in the presence of functional p53. J Cell Biol. 2004;165(4):473-482
214. Zhu W, Chen Y, Dutta A. Rereplication by depletion of geminin is seen regardless of p53 status and activates a G2/M checkpoint. Mol Cell Biol. 2004;24(16):7140-50
215. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008; 319(5868):1352-1355
216. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature. 2009;458(7237):438-444
217. Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer. 2005;104(9):1794-1807
218. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002;7(1):9-16
219. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004;5(5):417-421
220. Ling Y-H, Liebes L, Jiang J-D, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res. 2003;9(3):1145-1154
221. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917
222. Tobinai K. Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int J Clin Oncol. 2007;12(5):318-326
223. McCormack PL. Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma. Drugs. 2012;72(15):2023-2032
224. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomibnaive patients with relapsed and/or refractory multiple myeloma. Blood. 2012;119(24):5661-5670
225. Vij R, Siegel DS, Jagannath S, et al. An openlabel, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012;158(6):739-748
226. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101(6):2377-2380
227. Liu J, Furukawa M, Matsumoto T, Xiong Y. NEDD8 modification of CUL1 dissociates p120(CAND1), an inhibitor of CUL1-SKP1 binding and SCF ligases. Mol Cell. 2002; 10(6):1511-1518
228. Saha A, Deshaies RJ. Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. Mol Cell. 2008;32(1):21-31
229. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009; 458(7239):732-736
230. Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, Amidon B. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res. 2011;71(8):3042-3051
231. Wei D, Li H, Yu J, et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res. 2012;72(1):282-293
232. Yang D, Tan M, Wang G, Sun Y. The p21- dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. PLoS One. 2012;7(3):e34079.